Merck
  • Home
  • Search Results
  • Norfloxacin in the treatment of gonorrhea due to penicillinase and non-penicillinase producing Neisseria gonorrheae: a review.

Norfloxacin in the treatment of gonorrhea due to penicillinase and non-penicillinase producing Neisseria gonorrheae: a review.

Scandinavian journal of infectious diseases. Supplementum (1988-01-01)
C T Lee, E C Wong
ABSTRACT

In 12 recent clinical studies, norfloxacin given in various dosage regimens was shown to be highly effective in treating 1,588 gonococcal infections in 1,486 patients. A single oral dose of norfloxacin 800 mg cured 99.2% of 783 patients with penicillinase producing strains of Neisseria gonorrheae (PPNG) and non-penicillinase producing N. gonorrheae (NPPNG) causing urethritis, cervicitis and anorectal infections. A single oral dose of 800 mg of norfloxacin was found to be an effective alternative to a 2 g intramuscular dose of spectinomycin and superior to a 2.5 g oral dose of thiamphenicol for the treatment of PPNG urethritis or cervicitis. Its efficacy in treatment of NPPNG infections was shown to be similar to that of a single oral dose of 3.5 g of ampicillin plus 1 g of probenecid. Mild and transient gastrointestinal and neurological adverse events occurred in 3.3% of patients treated with norfloxacin 800 mg. Norfloxacin 800 mg as a single dose is recommended as an effective and safe single-dose treatment of urethritis, cervicitis and anorectal infections caused by PPNG or NPPNG.

MATERIALS
Product Number
Brand
Product Description

Norfloxacin for system suitability, European Pharmacopoeia (EP) Reference Standard
Supelco
Norfloxacin, analytical standard, ≥98% (TLC)
Norfloxacin, European Pharmacopoeia (EP) Reference Standard
Norfloxacin for peak identification, European Pharmacopoeia (EP) Reference Standard
Supelco
Norfloxacin, VETRANAL®, analytical standard